Name: Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
Uploaded: 2026-03-25T00:00:00.000Z

Join the leading experts as they go in-depth on some of the most important topics in dermatology. Hear invaluable insights on mechanism of disease, treatment options, and more for some of the most challenging dermatologic conditions.

Discourses in Dermatology

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

Chronic Spontaneous Urticaria (CSU)

Remibrutinib is a novel oral highly selective Bruton's tyrosine kinase inhibitor designed to prevent mast cell mediated release of histamines and other pro inflammatory mediators. Remix 1 and Remix 2 were multicenter randomized double blind placebo controlled phase 3 studies. Patients were randomized 2 to 1 to receive remibrutinib 25mg BID or placebo for 24 weeks followed by an open label period in which all patients received remibrutinib through week 52. This pooled analysis included about 600 patients in the rembrutinib group and about 300 in the placebo group with well balanced baseline characteristics. Remibrutinib demonstrated rapid improvement in disease activity compared with placebo. Reductions in weekly urticaria activity score or the UAS7 was were observed as early as week one with mean change from baseline of negative 11.8 versus negative 3.6 for placebo. The treatment difference continued through week 24 with changes of negative 22.4 for remibrutinib versus negative 15.4 for placebo. Similar early improvements were seen in itch severity and high severity scores. At week one, the mean change in weekly itch severity score was a negative 5.3 with remibrutinib compared with minus 1.8 for placebo and the high severity scores improved by minus 6.4 versus negative 1.8 respectively. Importantly, these benefits were sustained through week 52. Patients who initiated remibrutinib at baseline and those who transitioned from placebo achieved comparable reductions in the UAS 7, ISS 7 and HSS 7 by the end of the study. Rami brutinib also demonstrated favorable safety and tolerability across both studies. No deaths were reported, serious adverse events were infrequent and none were considered related to the study medication by investigators. The most common treatment emergent adverse events included COVID 19, nasopharyngitis and headache. In conclusion, Research Remix 1 and Remix 2 data showed that Remi brutinib provides rapid and sustained symptom improvement with a favorable safety profile in patients with CSU inadequately controlled by antihistamines. So it's wonderful to be able to offer to our patients an FDA approved oral medication which works quickly within days and the reduction of highs and itch with a reassuring safety profile.

How quickly can we meaningfully change symptoms in CSU, and does it last? Dr. Brownstone breaks down what the REMIX data suggest about speed, durability, and real-world relevance.In this explainer, Nicholas Brownstone, MD, walks through pooled phase 3 data from REMIX-1 and REMIX-2, focusing on what clinicians tend to notice first: how fast patients feel better. Improvements in UAS7, itch, and hive severity begin as early as week 1, with separation from placebo that continues through week 24 and holds out to week 52. &nbsp;Just as important, patients who started on placebo and later transitioned to remibrutinib reached similar levels of symptom control by the end of the study—pointing to both consistency and durability over time. The <a target="_blank" rel="noopener noreferrer" href="https://dermsquared.com/news-research/pooled-phase-3-data">full poster</a> adds context on safety and tolerability, but the takeaway here is straightforward: rapid onset paired with sustained control in a population that often cycles through incomplete responses.&nbsp;

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

Related CME